Browse > Article
http://dx.doi.org/10.7742/jksr.2019.13.3.381

Prognostic Analysis of Drug-Eluting Balloon Catheter and Drug-Eluting Stent for In-Stent Restenosis of Drug-Eluting Stent  

Lee, Doo Hwan (Department of Radiology, Dongshin University)
Song, Jong Nam (Department of Radiology, Dongshin University)
Park, Sin eui (Department of Radiology, Dongshin University)
Choi, Nam Gil (Department of Radiology, Dongshin University)
Han, Jae Bok (Department of Radiology, Dongshin University)
Kim, In Soo (Department of Radiology, Dongshin University)
Publication Information
Journal of the Korean Society of Radiology / v.13, no.3, 2019 , pp. 381-389 More about this Journal
Abstract
Although the development of Drug-eluting stent (DES) improved the ISR significantly more than the Bare metal stent (BMS), the coronary stent restenosis (ISR) treatment still has a high recurrence rate. This study is compared the efficacy of DEB with that of DES implantation in patients with ISR. Among 4,316 patients who underwent coronary stent implantation at the Chonnam National University Hospital between November 2012 and December 2016, 187 patients developed ISR on follow-up coronary angiography ($66.3{\pm}11.0years$, 123 males) were enrolled and divided into two groups according to revascularization method as group I (DEB group; n=127) and group II (DES group; n=60). Primary end point was defined as major adverse cardiac events (MACEs), composite of cardiac death (CD), myocardial infaction (MI), target lesion revascularization (TLR) and stent thrombosis (ST) during two-year follow-up between the two groups. There were no differences in the baseline characteristics and angiographic findings except that prevalence of device length was shorter ($21.1{\pm}5.3$ vs. $25.3{\pm}9.6 mm$, p<0.002) in group I.Two-year MACE were not different in the two groups (8.7%vs.10.0%, p=0.789). The incidences of cardiac death (0%vs.0%, p=1.000), MI (1.6%vs.6.7%, p=0.085), TLR(8.7% vs. 10.0%, p=0.789) and ST (0% vs. 0%, p=1000). DEB demonstrated comparable risk reduction for MACEs compared with DES in patients with ISR during two-year follow-up. DEB might be good alternative for the treatment of ISR in patients with ISR.
Keywords
Drug-eluting balloon; Drug-eluting stent; In-stent restenosis; Major adverse cardiac events;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Sang Rok Lee, Myung Ho Jeong, "Comparison of the Clinical Effect of Cutting Balloon Angioplasty and Drug-Eluting Stent for Treating the Focal Type of In-Stent Restenosis," Korean Circulation J, Vol. 36, No. 4, pp. 279-284, 2006.   DOI
2 I. S. Kim, J. B. Han, S. J. Jang, Y. I. Jang, "The Study on the Independent Predictive Factor of Restenosis after Percutaneous Coronary Intervention used Drug-Eluting Stent : Case on MDCT Calcium-Scoring Implementation Patient," Journal of Radiological Science and Technology, Vol. 33, No. 1, pp. 37-44, 2010.
3 J. E. Sousa, M. A. Costa, A. Abizaid, "Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and threedimensional intravascular ultrasound study," Circulation, Vol. 103, No. 2, pp. 192-195, 2001.   DOI
4 I. S. Kim, M. H. Jeong, S. J. Jang, J. B. Han, Y. I. Jang, "Clinical Outcomes of Stent Thrombosis after Drug-Eluting Coronary Stent Implantation," The Korea Contents Association, Vol. 13, No. 12, pp. 880-892, 2013.   DOI
5 Marie-Claude Morice, Patrick W. Serruys, J. Eduardo Sousa, Jean Fajadet, Ernesto Ban Hayashi, Marco Perin, Antonio Colombo, G. Schuler, Paul Barragan, Giulio Guagliumi, Ferenc Molnar, Robert Falotico, "A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization," N Engl J Med, Vol. 346, No. 23, pp. 1773-1780, 2002.   DOI
6 Stone GW, Ellis SG, Cox DA, Hermiller J, O' Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators, "A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease," N Engl J Med, Vol. 350, No. 3, pp. 221-231, 2004.   DOI
7 Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A; "ISAR-DIABETES Study Investigators, "Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients," N Engl J Med, Vol. 353, No. 7, pp. 663-670, 2005.   DOI
8 Saia F, Lemos PA, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Sianos G, Smits PC, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW, "Routine sirolimus eluting stent implantation for unselected in-stent restenosis; Insights from the rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital (Research) registry," Heart, Vol. 90, No. 10, pp. 1183-1188, 2004.   DOI
9 Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMario S, Hall P, Popma JJ, Koglin J, Russell ME, "TAXUS V Investigators. "Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease a randomized controlled trial," JAMA, Vol. 294, No. 10, pp. 1215-1223, 2005.   DOI
10 Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, Schomig A, "Sirolimus-eluting stent or paclitaxel- eluting stent vs. balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial," JAMA, Vol. 293, No. 2, pp. 165-171, 2005.   DOI
11 Holmes DR Jr, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA; SISR Investigators, "Sirolimus-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare-metal stents: The SISR randomized trial," JAMA, Vol. 295, No. 11, pp. 1264-1273, 2006.   DOI
12 Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G, "Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis," Circulation : Journal of the American Heart Association, Vol. 110, No. 7, pp. 810-814, 2004.   DOI
13 Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U, "Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter," N Engl J Med, Vol. 355, No. 20, pp. 2113-2124, 2006.   DOI
14 Scheller B, Hehrlein C, Bocksch W, Rutsh W, haghi D, Dietz U, Bohm M, Speck U, "Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter," Clin Res Cardiol, Vol. 97, No. 10, pp. 773-778, 2008.   DOI
15 Habara S, Mitsudo K, Kadota K, Goto T, Fujii S, Yamamoto H, Katoh H, Oka N, Fuku Y, Hosogi S, Hirono A, Maruo T, Tanaka H, Shigemoto Y, Hasegawa D, Tasaka H, Kusunose M, Otsuru S, Okamoto Y, Saito N, Tsujimoto Y, Eguchi H, Miyake K, Yoshino M, "Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis," JACC Cardiovascular Interventions, Vol. 4, No. 2, pp. 149-154, 2011.   DOI
16 Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, SchComig A, Kastrati A, "Randomized trial of paclitaxel versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for InStent Restenosis 2) study," J Am Coll Cardiol, Vol. 55, No. 24, pp. 2710-2716, 2010.   DOI
17 Mishkel GJ, Moore AL, Markwell S, Shelton MC, Sheton ME, "Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents," J Am Coll Cardiol, Vol. 49, No. 2, pp. 181-184, 2007.   DOI
18 B. Scheller, "Opportunities and limitations of drug-coated balloons in interventional therapies," Herz, Vol. 36, No. 3, pp. 232-239, 2011.   DOI
19 Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, Wong SC, Leon MB, "Small stent size and intimal hyperplasia contribute to restenosis: A volumetric intravascular ultrasound analysis," J Am Coll Cardiol, Vol. 26, No. 3, pp. 720-724, 1995.   DOI
20 Radke PW, Kobella S, Kaiser A, Franke A, Schubert D, Grube E, Hanrath P, Hoffmann R, "Treatment of in-stent restenosis using a paclitaxel-eluting stent: Acute results and long-term follow-up of a matched-pair comparison with intracoronary betaradiation therapy," Eur Heart J, Vol. 25, No. 11, pp. 920-925, 2004.   DOI
21 Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB, "Patterns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study," Circulation : Journal of the American Heart Association, Vol. 94, No. 6, pp. 1247-1254, 1996.   DOI
22 Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB, "Angiographic patterns of in-stent restenosis Classification and implications for long-term outcome," Circulation, Vol. 100, No. 18, pp. 1872-1878, 1999.   DOI
23 Rittger H, Brachmann J, Sinha AM, Waliszewski M, Ohlow M, Brugger A, Thiele H, Birkemeyer R, Kurowski V, Breithardt OA, Schmidt M, Zimmermann S, Lonke S, von Cranach M,Nguyen TV, Daniel WG, WCohrle J, "A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis," The PEPCAD-DES study. J Am Coll Cardiol, Vol. 59, No. 15, pp. 1377-1382, 2012.   DOI